Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas

Genes Chromosomes and Cancer

Volumn 49, Issue 11, 2010, Pages 1024-1034

  Gaedcke, Jochen ^a,b   Grade, Marian ^a,b   Jung, Klaus ^a   Camps, Jordi ^b   Jo, Peter ^a   Emons, Georg ^a   Gehoff, Anastasia ^c   Sax, Ulrich ^a   Schirmer, Markus ^a   Becker, Heinz ^a   Beissbarth, Tim ^a   Ried, Thomas ^b   Ghadimi, B Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; HISTONE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; NOVOBIOCIN; TRANSCRIPTOME;

ARTICLE; CANCER RESISTANCE; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PRIORITY JOURNAL; RECTUM CARCINOMA; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR GENE;

BIOPSY; DUAL-SPECIFICITY PHOSPHATASES; GENE EXPRESSION PROFILING; GENES, RAS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MUTATION; POLYMERASE CHAIN REACTION; RECTAL NEOPLASMS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77957907885     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20811     Document Type: Article

References (46)

1. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ. 1999. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96:6745-6750.
2. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. 2010. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790-799.
3. Balkwill F. 2009. Tumour necrosis factor and cancer. Nat Rev Cancer 9:361-371.
4. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57:289-300.
5. Bianchini M, Levy E, Zucchini C, Pinski V, Macagno C, De Sanctis P, Valvassori L, Carinci P, Mordoh J. 2006. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 29:83-94.
6. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193.
7. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruine AP, Goldbohm RA, van den Brandt PA. 2003. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24:703-710.
8. Cai Y, Jin J, Tomomori-Sato C, Sato S, Sorokina I, Parmely TJ, Conaway RC, Conaway JW. 2003. Identification of new subunits of the multiprotein mammalian TRRAP/TIP60-containing histone acetyltransferase complex. J Biol Chem 278:42733- 42736.
9. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthai A, Cuesta MA, Droste JSTS, Craanen M, Schrock E, Ylstra B, Meijer GA. 2009. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58:79-89.
10. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. 2008. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515.
11. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. 2007. Clinical relevance of KRAS mutation detection in meta-static colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166-1169.
12. Du KY, Herzig S, Kulkarni RN, Montminy M. 2003. TRB3: A tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574-1577.
13. Fang JY, Richardson BC. 2005. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322-327.
14. Fisher RA. 1925. Applications of "student's" distribution. Metron 5:90-104.
15. Friederichs J, Rosenberg R, Mages J, Janssen KP, Maeckl C, Nekarda H, Holzmann B, Siewert JR. 2005. Gene expression profiles of different clinical stages of colorectal carcinoma: Toward a molecular genetic understanding of tumor progression. Int J Colorectal Dis 20:391-402.
16. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, Wolff HA, Herrmann MK, Beissbarth T, Becker H, Ried T, Ghadimi M. 2010. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 94:76-81.
17. Glick AB. 2004. TGFbeta1, back to the future: Revisiting its role as a transforming growth factor. Cancer Biol Ther 3:276- 283.
18. Grade M, Ghadimi BM, Varma S, Simon R, Wangsa D, Barenboim-Stapleton L, Liersch T, Becker H, Ried T, Difilippantonio MJ. 2006. Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 66:267-282.
19. Grade M, Hormann P, Becker S, Hummon AB, Wangsa D, Varma S, Simon R, Liersch T, Becker H, Difilippantonio MJ, Ghadimi BM, Ried T. 2007. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 67:41-56.
20. Grade M, Hummon AB, Camps J, Emons G, Spitzner M, Gaedcke J, Hoermann P, Ebner R, Becker H, Difilippantonio MJ, Ghadimi BM, Beissbarth T, Caplan NJ, Ried T. 2010. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer Epub ahead of print.
21. Grzmil M, Kaulfuss S, Thelen P, Hemmerlein B, Schweyer S, Obenauer S, Kang TW, Burfeind P. 2006. Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. J Pathol 208:340-349.
22. Hallouin F, Goupille C, Rocher J, Le Pendu J. 1999. A rat experimental model for the design of vaccines against tumor associated antigens Tn and Sialyl-Tn. Glycoconjug J 16:681- 684.
23. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. 2004. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6:731-740.
24. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, Furukawa Y. 2006. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97:113-118.
25. Huo Q, Kinugasa T, Wang L, Huang J, Zhao J, Shibaguchi H, Kuroki M, Tanaka T, Yamashita Y, Nabeshima K, Iwasaki H, Kuroki M. 2009. Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer. Anticancer Res 29:851- 857.
26. Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, Campan M, Laird PW. 2008. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88:161-170.
27. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765.
28. Karnoub AE, Weinberg RA. 2008. Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol 9:517-531.
29. Katoh M. 2005. Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep 14:1381-1384.
30. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, III, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. 2007. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237.
31. Kinugasa T, Huo Q, Higash D, Shibaguchi H, Kuroki M, Tanaka T, Futami K, Yamashita Y, Hachimine K, Maekawa S, Nabeshima K, Iwasaki H, Kuroki M. 2007. Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res 27:3729-3734.
32. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995.
33. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. 2008. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379.
34. Liu HY, Zhou B, Wang L, Li Y, Zhou ZG, Sun XF, Xu B, Zeng YJ, Song JM, Luo HZ, Yang L. 2007. Association of E1AF mRNA expression with tumor progression and matrilysin in human rectal cancer. Oncology 73:384-388.
35. Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T. 2009. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life 62:194-199.
36. Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh J, Nosrati A, Willson JK, Mack D, Ried T, Markowitz S. 2002. Silence of chromosomal amplifications in colon cancer. Cancer Res 62:1134-1138.
37. Skandalis SS, Theocharis AD, Vynios DH, Papageorgakopoulou N, Hjerpe A, Karamanos NK, Theocharis DA. 2006. Cartilage aggrecan undergoes significant compositional and structural alterations during laryngeal cancer. Biochim Biophys Acta 1760:1046-1053.
38. Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
39. Stylianou M, Skandalis SS, Papadas TA, Mastronikolis NS, Theocharis DA, Papageorgakopoulou N, Vynios DH. 2008. Stage-related decorin and versican expression in human laryngeal cancer. Anticancer Res 28:245-251.
40. Tseng MY, Liu SY, Chen HR, Wu YJ, Chiu CC, Chan PT, Chiang WF, Liu YC, Lu CY, Jou YS, Chen JY. 2009. Serine protease inhibitor (SERPIN) B1 promotes oral cancer cell motility and is over-expressed in invasive oral squamous cell carcinoma. Oral Oncol 45:771-776.
41. Wang HY, Cheng Z, Malbon CC. 2003. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191:229-237.
42. Yip-Schneider MT, Lin A, Marshall MS. 2001. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 280:992-997.
43. Yuki D, Lin YM, Fujii Y, Nakamura Y, Furukawa Y. 2004. Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. Oncol Rep 12:275-280.
44. Zhang X, Jin B, Huang C. 2007. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 7:305-316.
45. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato F, Wang S, Olaru A Deacu E, Liu TC, Abraham JM, Meltzer SJ. 2002. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21:4855- 4862.
46. Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T. 2009. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett 280:78-85.